The Regulatory Framework
Law › Regulatory Framework › GLP
Good Laboratory Practice Compliance
GLP regulations govern data integrity in nonclinical laboratory studies—not animal welfare. But because a GLP failure can invalidate an entire study, these rules shape how beagles are housed, handled, documented, and ultimately used in ways the Animal Welfare Act never touches.
What GLP Means
Good Laboratory Practice (GLP) is a quality system for nonclinical laboratory studies that support applications for research or marketing permits for regulated products. The FDA codified GLP requirements in 21 CFR Part 58, first published in 1978 and still the governing standard for any nonclinical safety study submitted to the agency. The EPA maintains parallel frameworks under 40 CFR Part 160 (pesticides/FIFRA) and 40 CFR Part 792 (toxic substances/TSCA).
GLP does not tell scientists what to study or how to design experiments. It tells facilities how to organize, document, and preserve every element of a study so that regulators can reconstruct exactly what happened. When beagles are the test system, GLP requirements reach into housing conditions, veterinary care records, feeding protocols, and environmental controls—all framed as data quality measures rather than welfare protections.
Why GLP Matters for Animal Studies
Every nonclinical safety study that supports a drug, pesticide, or chemical approval must demonstrate that the data are reliable, reproducible, and traceable. If FDA or EPA determines that a study was conducted at a non-GLP-compliant facility, the study can be rejected outright. This means the animals used in that study—including beagles subjected to chronic toxicology protocols lasting months or years—were used for nothing.
For drug sponsors, GLP compliance is non-negotiable. A single Warning Letter from the FDA can halt a drug development program, delay approval by years, and cost hundreds of millions of dollars. Contract research organizations (CROs) that use beagles in toxicology studies—like Charles River Laboratories, Inotiv, and Labcorp Drug Development—stake their business models on maintaining GLP status.
Key GLP Requirements
Part 58 is organized into subparts covering every aspect of study conduct. The requirements most relevant to beagle studies include:
Every study must have a single designated study director who bears overall responsibility for the technical conduct and interpretation of the study, including final report accuracy.
An independent QAU must monitor each study to assure compliance with GLP regulations. The QAU inspects study phases, reviews the final report, and reports directly to management—not to the study director.
Written SOPs are required for every routine procedure, including animal room preparation, animal care, dosing, clinical observations, necropsy, data handling, and equipment maintenance. EPA’s Part 792 expressly requires SOPs for housing, feeding, handling, care, and isolation of newly received test animals.
All raw data, documentation, protocols, specimens, and final reports must be retained in archives for the period required by applicable regulations. Changes to raw data must be documented without obscuring the original entry—no erasures, no corrections without explanation.
Animal care facilities must be designed to separate species, isolate individual projects, and prevent cross-contamination. Environmental controls (temperature, humidity, lighting) must be documented because they can affect study outcomes.
When animals are the “test system,” GLP requires documentation of their source, arrival condition, quarantine, health status, housing conditions, and any veterinary treatment. Each animal must be uniquely identified. Diseased animals must be isolated and treated or disposed of.
PHS Policy & OLAW Oversight
Parallel to GLP, any institution receiving NIH, CDC, or FDA funding for biomedical research must comply with the PHS Policy on Humane Care and Use of Laboratory Animals, administered by the Office of Laboratory Animal Welfare (OLAW) within NIH. The Health Research Extension Act of 1985 (42 U.S.C. § 289d) requires these institutions to establish an IACUC and follow standards in the Guide for the Care and Use of Laboratory Animals.
Assurance model: Institutions file a formal Assurance with OLAW committing to the Guide’s standards. AWA regulations serve as the minimum floor; the Guide becomes the operating ceiling.
Euthanasia standards: Must follow AVMA guidelines unless scientifically justified in writing.
IACUC reviews: Semiannual program reviews and facility inspections are required, with flexibilities clarified under the 21st Century Cures Act.
Enforcement: OLAW can withhold, suspend, or terminate awards. But the model depends substantially on institutions self-reporting noncompliance. A GAO report on NIH oversight of foreign animal research described oversight that depends on internal reporting and referral mechanisms.
AAALAC Accreditation: Voluntary but Expected
The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) is a private, nonprofit organization that provides voluntary accreditation for animal research programs. While not legally required, AAALAC accreditation is treated as a de facto standard across the industry. Major pharmaceutical companies routinely require their CRO partners to maintain AAALAC status. Federal agencies including DoD and VA reference AAALAC accreditation in their animal use policies.
How GLP Intersects with AWA Compliance
GLP and the Animal Welfare Act regulate the same facilities from different directions. The AWA sets minimum standards for animal housing, veterinary care, and handling. GLP requires that those conditions be documented, controlled, and reproducible because environmental variables can compromise study data. In practice, the two regimes create overlapping but non-identical compliance obligations:
| Domain | AWA Requires | GLP Requires |
|---|---|---|
| Housing | Minimum space, ventilation, sanitation | Documented environmental controls, separation by study |
| Veterinary Care | Adequate vet program, pain management | Documented health records, treatment logs, disease isolation |
| Record-Keeping | Annual reports, protocol reviews | Complete raw data retention, audit trails, QAU oversight |
| Inspections | USDA/APHIS unannounced inspections | FDA surveillance inspections, data audits |
| Enforcement | Civil penalties, license actions | Study rejection, facility disqualification, Warning Letters |
A facility can be fully GLP-compliant while operating at the bare minimum of AWA standards. The regulations serve different masters: GLP protects data; AWA (nominally) protects animals.
The Paradox: Data Quality Without Animal Welfare
GLP’s primary purpose is data quality and integrity, not animal welfare. This creates a structural paradox that defines the regulatory experience of research beagles: the most rigorous documentation requirements in the system exist not to protect animals but to protect the reliability of data extracted from their bodies.
A GLP-compliant facility will meticulously document a beagle’s declining health over a 90-day toxicology study—weight loss, organ damage, behavioral changes—because those observations are the data points the study exists to generate. The documentation does not trigger intervention to reduce suffering; it records suffering as scientific output. The study protocol, approved by the IACUC, defines humane endpoints, but GLP itself has no opinion on when suffering becomes unacceptable.
FDA Form 483 Observations & Warning Letters
When FDA inspectors identify GLP violations during a facility inspection, they document them on Form 483—a list of inspectional observations. These are not formal enforcement actions but serve as notice that the agency has identified deviations. The facility must respond with corrective actions. If problems persist or are severe, FDA escalates to a Warning Letter, which is public, names the facility, and details the violations.
- Failure to follow written SOPs
- Incomplete or inaccurate raw data
- QAU not conducting required inspections
- Study director failing to approve protocol amendments
- Inadequate documentation of animal health or test article administration
- Equipment not properly calibrated or maintained
- Archive integrity failures
- Public disclosure of facility name and violations
- Sponsors may pull studies from the facility
- Pending drug applications may be questioned
- Repeated violations can lead to facility disqualification
- Criminal prosecution possible in cases involving fraud
- Studies conducted during noncompliance may be rejected
What Happens When GLP Fails
GLP failure cascades through the entire drug development pipeline. When FDA determines that a nonclinical study was not conducted in accordance with GLP, the consequences are severe and compounding:
FDA may refuse to accept study data in an IND, NDA, or BLA submission. The sponsor loses months or years of work and the associated investment.
The study must be repeated at a compliant facility. New beagles are acquired, subjected to the same protocol, and euthanized for necropsy—doubling the animal cost of the same scientific question.
Approval timelines extend by the duration of the repeat study plus regulatory review. For a chronic toxicology study in beagles, this can mean 12–18 months of additional delay.
Under 21 CFR 58.202, FDA can initiate disqualification proceedings that bar a facility from conducting any future GLP studies. This is a business death sentence for a CRO.
If unreliable nonclinical data are not caught, a drug with hidden toxicity risks may advance to human clinical trials. GLP exists because this has happened.